[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F: Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant; 2001 Sep;28(6):551-6
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topotecan appears to be relatively unaffected by the most common multidrug resistance mechanisms, may potentiate cytotoxicity of alkylators, has good penetration into the central nervous system, is active against a variety of neoplasms, and has myelosuppression as its paramount toxicity.
  • Twenty-one patients with poor-prognosis tumors and intact function of key organs received topotecan 2 mg/m2 by 30-min intravenous (i.v.) infusion on days -8, -7, -6, -5, -4; thiotepa 300 mg/m2 by 3 h i.v. infusion on days -8, -7, -6; and carboplatin by 4 h i.v. infusion on days -5, -4, -3 with a daily dose derived from the pediatric Calvert formula, using a targeted area under the curve of seven mg/ml* min ( approximately 500 mg/m2/day).
  • Post-transplant treatment included radiotherapy alone (four patients) or plus biological agents (11 patients with neuroblastoma).
  • With a follow-up of 6+ to 32+ (median 11+) months, event-free survivors include 10/11 neuroblastoma patients (first CR), 4/5 brain tumor patients (second PR or CR), 1/3 patients with metastatic Ewing's sarcoma (first or second CR), and a patient transplanted for multiply recurrent immature ovarian teratoma; a patient with desmoplastic small round-cell tumor (second PR) had progressive disease at 8 months.
  • Favorable results for disease control, manageable toxicity, and the antitumor profiles of topotecan, thiotepa, and carboplatin, support use of this three-drug regimen in the treatment of neuroblastoma and brain tumors; applicability to other tumors is still uncertain.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Carboplatin / administration & dosage. Neuroblastoma / drug therapy. Thiotepa / administration & dosage. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11607767.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


2. Gardner SL, Asgharzadeh S, Green A, Horn B, McCowage G, Finlay J: Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer; 2008 Aug;51(2):235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
  • BACKGROUND: Central nervous system (CNS) atypical teratoid rhabdoid tumors (AT/RT) are rare tumors of childhood with a dismal prognosis.
  • Historically, surgery and standard dose chemotherapy have resulted in a median survival of 8.5 months from diagnosis.
  • METHODS: Thirteen children newly diagnosed with CNS AT/RT were treated with either the "Head Start I" (HS I) or "Head Start II" (HS II) regimens.
  • Therapy included resection followed by five cycles of cisplatin, vincristine, cyclophosphamide, and etoposide.
  • Eight patients died of disease (six on HS I); one patient died from infection; one patient died from secondary malignancy following treatment for recurrent AT/RT.
  • CONCLUSION: Three of seven children with CNS AT/RT treated on HS II have experienced long term remissions.
  • Long term survival can be achieved in a subset of young children with CNS AT/RT following resection with the use of multi-drug chemotherapy including high dose methotrexate and myeloablative chemotherapy without radiation therapy (RT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381756.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Finkelstein-Shechter T, Gassas A, Mabbott D, Huang A, Bartels U, Tabori U, Janzen L, Hawkins C, Taylor M, Bouffet E: Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol; 2010 Jul;32(5):e182-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy.
  • PURPOSE: To retrospectively review an institutional experience in managing atypical teratoid/rhabdoid tumors (AT/RT) of the Central Nervous System with high-dose chemotherapy in infants and children less than 4 years old.
  • Two of these patients did not receive any active therapy.
  • After surgery, the 6 remaining patients received induction therapy followed by sequential high-dose chemotherapy with autologous stem cell rescue.
  • CONCLUSIONS: This experience confirms that a subset of young AT/RT patients may achieve long-term survival with intensive and high-dose chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Rhabdoid Tumor / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infant. Male. Neoplasm Metastasis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Pediatr Hematol Oncol. 2011 Jul;33(5):400. Laura, Janzen [corrected to Janzen, Laura]
  • (PMID = 20495479.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Bambakidis NC, Robinson S, Cohen M, Cohen AR: Atypical teratoid/rhabdoid tumors of the central nervous system: clinical, radiographic and pathologic features. Pediatr Neurosurg; 2002 Aug;37(2):64-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumors of the central nervous system: clinical, radiographic and pathologic features.
  • INTRODUCTION: Atypical teratoid/rhabdoid tumors (ATT/RT) of the central nervous system (CNS) are uncommon malignancies of childhood with an aggressive course and a uniformly fatal outcome.
  • RESULTS: Eight children underwent surgery for CNS ATT/RT at our institution since 1996.
  • Four tumors had multifocal disease at the time of diagnosis.
  • Six patients received multiagent chemotherapy including 3 patients with autologous bone marrow transplantation, and 6 patients received radiation therapy.
  • Median survival was 9 months from the time of diagnosis.
  • CONCLUSIONS: In spite of aggressive therapy, the prognosis for ATT/RT remains dismal.
  • The search for effective treatment strategies will require a better understanding of the biology and molecular genetics of this tumor.
  • [MeSH-major] Central Nervous System Neoplasms / diagnostic imaging. Central Nervous System Neoplasms / pathology. Rhabdoid Tumor / diagnostic imaging. Rhabdoid Tumor / pathology. Teratoma / diagnostic imaging. Teratoma / pathology
  • [MeSH-minor] Adolescent. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12145514.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Garrè ML, Tekautz T: Role of high-dose chemotherapy (HDCT) in treatment of atypical teratoid/rhabdoid tumors (AT/RTs). Pediatr Blood Cancer; 2010 Apr;54(4):647-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of high-dose chemotherapy (HDCT) in treatment of atypical teratoid/rhabdoid tumors (AT/RTs).
  • Atypical teratoid/rhabdoid tumors (AT/RTs) of the CNS have been recently characterized as a distinct clinicopathologic entity with an unusually poor prognosis and with the highest incidence in the first 2 years of life.
  • AT/RT of the CNS is a usually fatal disease virtually unresponsive to chemotherapy (CT) and radiotherapy (RT).
  • Rapid progression and CNS dissemination are commonly reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Rhabdoid Tumor / drug therapy. Teratoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146222.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 18
  •  go-up   go-down


6. Zimmerman MA, Goumnerova LC, Proctor M, Scott RM, Marcus K, Pomeroy SL, Turner CD, Chi SN, Chordas C, Kieran MW: Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol; 2005 Mar;72(1):77-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor.
  • Atypical teratoid/rhabdoid tumors (AT/RT) are highly malignant lesions of childhood that carry a very poor prognosis.
  • AT/RT can occur in the central nervous system (CNS AT/RT) and disease in this location carries an even worse prognosis with a median survival of 7 months.
  • In spite of multiple treatment regimens consisting of maximal surgical resection (including second look surgery), radiation therapy (focal and craniospinal), and multi-agent intravenous, oral and intrathecal chemotherapy, with or without high-dose therapy and stem cell rescue, only seven long-term survivors of CNS AT/RT have been reported, all in patients with newly diagnosed disease.
  • For this reason, many centers now direct such patients, particularly those under 5 years of age, or those with recurrent disease, towards comfort care rather than attempt curative therapy.
  • We now report on four children, two with newly diagnosed CNS AT/RT and two with progressive disease after multi-agent chemotherapy who are long term survivors (median follow-up of 37 months) using a combination of surgery, radiation therapy, and intensive chemotherapy.
  • The chemotherapy component was modified from the Intergroup Rhabdomyosarcoma Study Group (IRS III) parameningeal protocol as three of the seven reported survivors in the literature were treated using this type of therapy.
  • Our four patients, when added to the three reported survivors in the literature using this approach, suggest that patients provided this aggressive therapy can significantly alter the course of their disease.
  • More importantly, we report on the first two survivors after relapse with multi-agent intravenous and intrathecal chemotherapy treated with this modified regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Female. Humans. Infant. Male. Radiotherapy, Adjuvant / methods. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(4):393-7 [3125680.001]
  • [Cites] Childs Nerv Syst. 1993 Jun;9(3):185-90; discussion 190 [8397069.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):31-7 [10738300.001]
  • [Cites] Arch Ophthalmol. 1967 Dec;78(6):709-13 [4294312.001]
  • [Cites] Surg Neurol. 1992 May;37(5):410-4 [1631771.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):37-40 [7459813.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):418-21 [9298280.001]
  • [Cites] Surv Ophthalmol. 1994 Jan-Feb;38(4):365-70 [8160109.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Semin Diagn Pathol. 1986 May;3(2):151-63 [3616219.001]
  • [Cites] J Neurooncol. 1999 May;43(1):63-70 [10448873.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):310-7 [2056976.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):710-4 [2213160.001]
  • [Cites] Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1989 Sep-Oct;30(5):316-22 [2484056.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2000 May;48(1):41-5 [11026695.001]
  • [Cites] Can J Neurol Sci. 1994 Aug;21(3):273-7 [8000986.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14 (1):107-15 [8427070.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):429-34 [8211663.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Jun;29(3):254-61 [12787322.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):265-75 [10066100.001]
  • [Cites] J Neurooncol. 1995;25(3):193-203 [8592169.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1727-8 [7502982.001]
  • [Cites] Pediatr Neurol. 1995 Jul;13(1):65-8 [7575853.001]
  • [Cites] Acta Neuropathol. 1996;91(6):578-86 [8781656.001]
  • [Cites] J Korean Med Sci. 2002 Oct;17(5):723-6 [12378033.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):219-25 [12675315.001]
  • [Cites] Pediatr Radiol. 2003 Apr;33(4):275-7 [12709762.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):389-91 [10219345.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):214-22 [7619723.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):23-8 [8191632.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):53-6 [11763423.001]
  • [Cites] Neurology. 1991 Nov;41(11):1847-8 [1944923.001]
  • [Cites] Clin Neuropathol. 1991 Jan-Feb;10(1):1-10 [2015720.001]
  • [Cites] Childs Nerv Syst. 1987;3(6):379-81 [3450389.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Comput Assist Tomogr. 1990 May-Jun;14 (3):461-3 [2335617.001]
  • [Cites] Pediatr Neurosurg. 1994;21(4):232-6 [7865408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800 [11095756.001]
  • [Cites] Pediatr Pathol. 1989;9(3):307-19 [2546137.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):244-8 [12682757.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] Postgrad Med J. 1998 Jun;74(872):369-70 [9799897.001]
  • [Cites] Childs Nerv Syst. 2000 Apr;16(4):228-34 [10855521.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • (PMID = 15803379.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


7. Matsutani M, Japanese Pediatric Brain Tumor Study Group: Combined chemotherapy and radiation therapy for CNS germ cell tumors--the Japanese experience. J Neurooncol; 2001 Sep;54(3):311-6
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and radiation therapy for CNS germ cell tumors--the Japanese experience.
  • Among intracranial germ cell tumors, nongerminomatous tumors have proved refractory to conventional treatment with surgery and irradiation.
  • Since 1983, chemotherapy has been delivered in Japan as an adjuvant therapy in patients with intracranial nongerminomatous germ cell tumors.
  • Based on our clinical experience, we undertook a multi-institutional phase II study to establish post-surgical combined chemotherapy and radiation therapy for primary germ cell tumors in the brain.
  • We adopted carboplatin-etoposide (CARB-VP) or cisplatin-etoposide (PE) combination chemotherapy for patients with germinomas and those with tumors that placed them in the intermediate prognosis group, and ifosphamide-cisplatin-etoposide (ICE) for patients with tumors that placed them in the poor prognosis group.
  • Among patients with germinoma (n = 75), the rate or complete remission after combination therapy was 92.0%; it was 67.8% for patients in the intermediate prognosis group (n = 28).
  • Of 9 patients with a poor prognosis, 4 experienced disease progression during treatment and died within 10 months.
  • There were no serious complications attributable to the combination therapy.
  • Our treatment protocols are effective for patients with germinomas and those with an intermediate prognosis.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Germinoma / drug therapy. Germinoma / radiotherapy. Postoperative Care. Teratoma / drug therapy. Teratoma / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Prognosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):285-90 [3403311.001]
  • [Cites] No Shinkei Geka. 1984 Feb;12 (2):161-8 [6717740.001]
  • [Cites] Aust N Z J Surg. 1992 Jun;62(6):436-40 [1590711.001]
  • [Cites] Surg Neurol. 1975 Jan;3(1):49-54 [1111147.001]
  • [Cites] Am J Clin Oncol. 1984 Aug;7(4):327-30 [6331151.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):103-7 [3880652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):541-5 [2318686.001]
  • [Cites] Eur J Pediatr. 1987 May;146(3):233-45 [3595642.001]
  • [Cites] Cancer. 1968 Sep;22(3):533-44 [5673233.001]
  • [Cites] Neurosurgery. 1983 Jul;13(1):40-3 [6877562.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] Pediatr Res. 1989 Jun;25(6):561-7 [2662128.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Neurosurgery. 1985 May;16(5):696-700 [4000445.001]
  • [Cites] Neurosurg Focus. 1998 Jul 15;5(1):e7 [17140188.001]
  • [Cites] Surg Neurol. 1994 Sep;42(3):200-10 [7940105.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):247-56 [1517802.001]
  • [Cites] Gan No Rinsho. 1986 Sep;32(11):1387-93 [2430119.001]
  • [Cites] Cancer. 1979 Jul;44(1):281-4 [455253.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Neurosurgery. 1981 Jun;8(6):656-68 [6269016.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):429-33 [2394620.001]
  • [Cites] J Neurooncol. 1985;3(2):147-52 [3897472.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):826-30 [3998830.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):59-62 [9548343.001]
  • [Cites] Acta Neurochir (Wien). 1993;120(3-4):111-7 [7681619.001]
  • (PMID = 11767296.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Packer RJ, Biegel JA, Blaney S, Finlay J, Geyer JR, Heideman R, Hilden J, Janss AJ, Kun L, Vezina G, Rorke LB, Smith M: Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol; 2002 Jun-Jul;24(5):337-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop.
  • Childhood atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system (CNS) is a recently described entity.
  • The tumor's incidence is still undefined, but it may comprise as high as 1 in 4 primitive CNS tumors in infants.
  • Treatment is far from optimal, but there are occasional long-term survivors, especially among older children.
  • Therapeutic approached have included surgery, chemotherapy, and radiotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child, Preschool. Chromosomal Proteins, Non-Histone. Chromosome Deletion. Chromosomes, Human, Pair 22 / genetics. DNA-Binding Proteins / genetics. General Surgery. Humans. Infant. Monosomy. Neoplasm Proteins / genetics. Radiotherapy. Transcription Factors

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12142780.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Congresses; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


9. de León-Bojorge B, Rueda-Franco F, Anaya-Jara M: Central nervous system atypical teratoid rhabdoid tumor: experience at the National Institute of Pediatrics, Mexico City. Childs Nerv Syst; 2008 Mar;24(3):307-12
Genetic Alliance. consumer health - Rhabdoid tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system atypical teratoid rhabdoid tumor: experience at the National Institute of Pediatrics, Mexico City.
  • OBJECTIVE: The purpose of this study is to present our experience with ten cases of Central nervous system atypical teratoid rhabdoid tumor (CNS/ATRT).
  • PATIENTS AND METHODS: A series of ten patients with CNS/ATRT, were diagnosed and treated between 1990 and 2005, at the National Institute of Pediatrics, in Mexico City.
  • The gender, age of presentation, clinical features, tumor localization, imaging studies, grade of tumor resection, complications, adjuvant therapy, and survival are presented.
  • There were two cases with longer survival (9 and 16 months), and their tumors were resected in total or subtotal manner and received adjuvant therapy (radiotherapy and chemotherapy).
  • CONCLUSIONS: Preliminary results, show that in older children, we can improve their survival with the subtotal or total resection of the tumor and the addition of chemotherapy and radiotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Infratentorial Neoplasms / pathology. Rhabdoid Tumor / pathology. Supratentorial Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Hydrocephalus / etiology. Hydrocephalus / pathology. Infant. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1992 May;37(5):410-4 [1631771.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):418-21 [9298280.001]
  • [Cites] Rev Neurol. 2001 Apr 1-15;32(7):618-24 [11391487.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):204-9 [7619721.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):710-4 [2213160.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):429-34 [8211663.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):327-32 [12746165.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1727-8 [7502982.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] Indian J Pediatr. 2005 Aug;72(8):693-6 [16131776.001]
  • [Cites] Pediatr Neurosurg. 1994;21(4):232-6 [7865408.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • (PMID = 17876589.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Athale UH, Duckworth J, Odame I, Barr R: Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol; 2009 Sep;31(9):651-63
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies.
  • PURPOSE: Therapy for central nervous system (CNS) atypical teratoid rhabdoid tumor (ATRT) is controversial.
  • We describe 4 children treated with sarcoma-like therapy and review the literature to evaluate outcome in relation to treatment modalities.
  • PROCEDURE: Reports from 1995 to 2007, describing clinical features of children (< or =18 years) were reviewed for details of demography, therapy, and outcome.
  • Kaplan-Meier survival analyses were used to study the impact of clinical features, demography, and therapy on overall survival (OS).
  • RESULTS: The median OS for patients treated with multiagent chemotherapy (n=79) was 17.3 months (range, 1.5-93 mo); unrelated to age at diagnosis, sex, tumor site, and extent of resection.
  • Patients (n=30) treated with intrathecal (IT) chemotherapy had significantly higher 2-year OS [64% (95% confidence interval, 46.5-82.0) vs. 17.3% (95% confidence interval, 5.4-29.3); P<0.0001] and lower prevalence of distant CNS metastasis compared with those without IT therapy (n=49) (20% vs. 59.2%; P=0.001).
  • CONCLUSIONS: Despite dismal OS, multimodal therapy can induce remission even in metastatic CNS ATRT with partial resection.
  • IT chemotherapy results in higher OS and, because of an overall high rate of distant relapse, should be considered in future trials.
  • [MeSH-major] Brain Neoplasms / epidemiology. Rhabdoid Tumor / epidemiology. Teratoma / epidemiology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Infant. Infant, Newborn. Injections, Spinal. Kaplan-Meier Estimate. Male. Prognosis. Prospective Studies. Spinal Neoplasms / diagnosis. Spinal Neoplasms / drug therapy. Spinal Neoplasms / epidemiology. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707161.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Ertan Y, Sezak M, Turhan T, Kantar M, Erşahin Y, Mutluer S, Vergin C, Oniz H, Akalin T: Atypical teratoid/rhabdoid tumor of the central nervous system: clinicopathologic and immunohistochemical features of four cases. Childs Nerv Syst; 2009 Jun;25(6):707-11
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the central nervous system: clinicopathologic and immunohistochemical features of four cases.
  • All of the patients died within a mean of 14 months due to tumor progression despite the chemotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2009 Nov;25(11):1387; author reply 1389 [19636570.001]
  • [Cites] Pediatr Neurosurg. 2006;42(3):187-92 [16636624.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):309-13 [16195799.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):321-30 [18369529.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):265-75 [10066100.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Neuropathology. 2002 Dec;22(4):252-60 [12564764.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jul;39(7):510-7; discussion 517-8 [10437379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):482-8 [10805090.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):369-78 [9206002.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):143-7 [17968559.001]
  • (PMID = 19212771.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / S100 Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Synaptophysin; 0 / Transcription Factors; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


12. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • METHODS: Twenty patients with histologically diagnosed localized pure germinoma (n = 19) or germinoma with a mature teratoma component (n = 1) received four cycles of carboplatin and etoposide at 3-week intervals.
  • In 18 patients, chemotherapy was followed by whole ventricular irradiation to 21.6-25.5 Gy with a simultaneous integrated or sequential primary site boost to 30-30.6 Gy.
  • Neurocognitive function was evaluated periodically following treatment.
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Hale GA, Greenwood MF, Geil JD, Moscow JA: Langerhans cell histiocytosis after therapy for a malignant germ cell tumor of the central nervous system. J Pediatr Hematol Oncol; 2000 Jul-Aug;22(4):355-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Langerhans cell histiocytosis after therapy for a malignant germ cell tumor of the central nervous system.
  • The 8-year-old boy was treated for an immature teratoma of the posterior fossa with gross total resection and craniospinal irradiation preceding bleomycin, etoposide, and vinblastine chemotherapy for four cycles.
  • Seven months after completion of therapy, he experienced multifocal bone disease with LCH.
  • [MeSH-major] Bone Neoplasms / etiology. Brain Neoplasms / pathology. Histiocytosis, Langerhans-Cell / etiology. Neoplasms, Second Primary / etiology. Teratoma / pathology


14. Serowka K, Chiu Y, Gonzalez I, Gilles F, McComb G, Krieger M, Dhall G, Britt B, Ji L, Sposto R, Finlay JL: Central nervous system (CNS) tumors in the first six months of life: the Children's Hospital Los Angeles experience, 1979-2005. Pediatr Hematol Oncol; 2010 Mar;27(2):90-102
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system (CNS) tumors in the first six months of life: the Children's Hospital Los Angeles experience, 1979-2005.
  • BACKGROUND: The authors report the experience at the Children's Hospital Los Angeles with brain tumors diagnosed before 6 months of age, describing the characteristics of the patients, their tumors, treatment strategies, and prognostic factors.
  • There were 11 gliomas, 9 choroid plexus tumors, 8 medulloblastomas and supratentorial primitive neuroectodermal tumors (PNET), 2 atypical teratoid/rhabdoid tumors (ATRT), and 1 each of ependymoma, craniopharyngioma, and immature teratoma.
  • The treatment strategies included 5 patients with biopsy only, 18 less than gross total resections (<GTRx), and 9 GTRx.
  • Fourteen children (42%) received chemotherapy.
  • [MeSH-minor] Female. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Los Angeles / epidemiology. Male. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201690.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA: Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol; 2004 Jul 15;22(14):2877-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.
  • PURPOSE: Atypical teratoid/rhabdoid tumor (AT/RT) of the CNS is an extremely rare and aggressive tumor of early childhood.
  • The poor outcome with conventional infant brain tumor therapy has resulted in a lack of clear treatment guidelines.
  • Primary therapy included chemotherapy in all patients, radiotherapy in 13 patients (31%), stem-cell rescue in 13 patients (31%), and intrathecal chemotherapy in 16 patients (38%).
  • CONCLUSION: Aggressive therapy has prolonged the natural history in a subset of children.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Registries. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15254056.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 46274
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


16. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A: Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol; 2005 Mar 1;23(7):1491-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
  • PURPOSE: To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH).
  • All patients underwent surgical resection; 30 received subsequent chemotherapy.
  • Three of four patients 3 years or older with progressive disease were successfully rescued with ifosfamide, carboplatin, and etoposide therapy.
  • ATRT presenting in older patients can be cured using a combination of radiation and high-dose alkylating therapy.
  • Older patients with relapsed ATRT can have salvage treatment using ICE chemotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Prognosis. Survival Rate. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735125.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SMARCC1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


17. Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, Yen SH: Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1038-43
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience).
  • PURPOSE: To assess outcomes and prognostic factors in radiotherapy of pediatric central nervous system atypical teratoid/rhabdoid tumor (AT/RT).
  • METHODS AND MATERIALS: Seventeen patients with central nervous system AT/RT were retrospectively reviewed after curative radiotherapy as primary or adjuvant therapy between January 1990 and December 2003.
  • The log-rank method was used to compare the effects of dosage (>50 Gy or < or =50 Gy) and treatment duration (>45 days or < or =45 days).
  • Multivariate analysis revealed a significant relationship between the following: overall survival and performance status (p = 0.019), failure-free survival and total irradiation dose (p = 0.037), time interval between surgery and radiotherapy initiation (p = 0.031), and time interval between surgery and radiotherapy end point (p = 0.047).
  • CONCLUSION: Radiotherapy is crucial in the treatment of AT/RT.
  • We recommend initiating radiotherapy immediately postoperatively and before systemic chemotherapy in pediatric patients > or =3 years of age.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Rhabdoid Tumor / radiotherapy. Teratoma / radiotherapy

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1273; author reply 1273-4 [16798419.001]
  • (PMID = 16406394.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Squire SE, Chan MD, Marcus KJ: Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy. J Neurooncol; 2007 Jan;81(1):97-111
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy.
  • To date, approximately 200 cases of atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system have been described in the literature.
  • This CNS tumor tends to present at an age of less than 3 years, and most patients succumb to their disease within 1 year of diagnosis.
  • However, lessons learned from regimens based upon medulloblastoma have revealed that AT/RT requires more aggressive treatment.
  • A significant portion of patients die of local recurrence in spite of aggressive surgery and chemotherapy.
  • As most patients with AT/RT present as infants or young children, radiation therapy has been a less than standard treatment option.
  • However, recent evidence suggests that long-term survival can occur with use of more aggressive treatment approaches including dose-intense chemotherapy as well as adjuvant radiation therapy.
  • A standardized and effective approach to treating this usually fatal tumor remains elusive, and the role of radiation therapy presents a particular dilemma as young patients with this disease may experience devastating late effects of therapy if they achieve a long-term survival.
  • Review of the literature reveals an association between initial radiation therapy and the ability to achieve a prolonged survival.
  • Our review underscores the importance or enrolling patients in multi-institutional prospective studies to further investigate the value of radiation to treat this pediatric neoplasm.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Radiotherapy / methods. Rhabdoid Tumor / radiotherapy. Teratoma / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Humans

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(4):393-7 [3125680.001]
  • [Cites] Childs Nerv Syst. 1993 Jun;9(3):185-90; discussion 190 [8397069.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):573-80 [16054568.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):727-34 [14967427.001]
  • [Cites] Surg Neurol. 1992 May;37(5):410-4 [1631771.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):304-10 [15558704.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):418-21 [9298280.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):494-8 [12507084.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1660-6 [2809681.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Semin Diagn Pathol. 1986 May;3(2):151-63 [3616219.001]
  • [Cites] Neuroradiology. 2004 Oct;46(10 ):834-7 [15322781.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):379-85 [10229502.001]
  • [Cites] J Neurooncol. 1999 May;43(1):63-70 [10448873.001]
  • [Cites] Neurol India. 1999 Dec;47(4):314-7 [10625907.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):710-4 [2213160.001]
  • [Cites] Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1989 Sep-Oct;30(5):316-22 [2484056.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):555-62 [8630965.001]
  • [Cites] Can J Neurol Sci. 1994 Aug;21(3):273-7 [8000986.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14 (1):107-15 [8427070.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1841-6 [4027923.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):129-30 [16411024.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3470-6 [11481352.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):429-34 [8211663.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):327-32 [12746165.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Jun;29(3):254-61 [12787322.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):47-52 [14756440.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):265-75 [10066100.001]
  • [Cites] J Neurooncol. 1995;25(3):193-203 [8592169.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1727-8 [7502982.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):254-60 [14752863.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):585-97 [14628124.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):267-8 [16086409.001]
  • [Cites] Yonsei Med J. 2001 Feb;42(1):142-6 [11293495.001]
  • [Cites] Acta Neuropathol. 1996;91(6):578-86 [8781656.001]
  • [Cites] J Korean Med Sci. 2002 Oct;17(5):723-6 [12378033.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):219-25 [12675315.001]
  • [Cites] Pediatr Radiol. 2003 Apr;33(4):275-7 [12709762.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):389-91 [10219345.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] Neuropathology. 2002 Dec;22(4):252-60 [12564764.001]
  • [Cites] Childs Nerv Syst. 1995 Jun;11(6):340-5; discussion 345-6 [7671269.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):214-22 [7619723.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):23-8 [8191632.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):53-6 [11763423.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4726-34 [16034048.001]
  • [Cites] Pediatr Neurosurg. 2000 Aug;33(2):105-11 [11070438.001]
  • [Cites] Clin Neuropathol. 1991 Jan-Feb;10(1):1-10 [2015720.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):481-3 [15037476.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):342-9 [12593621.001]
  • [Cites] Clin Radiol. 1996 Jan;51(1):65-6 [8549052.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):323-8 [11782395.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] Indian J Pediatr. 2005 Aug;72(8):693-6 [16131776.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):241-52 [15980975.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):476-80 [15037475.001]
  • [Cites] Singapore Med J. 2004 Jun;45(6):286-8 [15181525.001]
  • [Cites] J Comput Assist Tomogr. 1990 May-Jun;14 (3):461-3 [2335617.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):489-93 [12507083.001]
  • [Cites] Neurol India. 2003 Jun;51(2):297-8 [14571049.001]
  • [Cites] Neurosurgery. 2005 May;56(5):936-45; discussion 936-45 [15854241.001]
  • [Cites] Pediatr Neurosurg. 1994;21(4):232-6 [7865408.001]
  • [Cites] Pediatr Neurosurg. 2002 Aug;37(2):64-70 [12145514.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Yonsei Med J. 2000 Feb;41(1):8-16 [10731913.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):244-8 [12682757.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):65-70 [15690353.001]
  • [Cites] Pediatr Radiol. 2003 Aug;33(8):554-8 [12759791.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):85-8 [15803380.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] Childs Nerv Syst. 2000 Apr;16(4):228-34 [10855521.001]
  • [Cites] Neuroradiology. 1997 Oct;39(10):719-23 [9351109.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):188-96 [12778010.001]
  • [Cites] Acta Neurochir (Wien). 2003 Aug;145(8):663-6; discussion 666 [14520545.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):369-78 [9206002.001]
  • (PMID = 16855864.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 92
  •  go-up   go-down


19. Wang CH, Hsu TR, Wong TT, Chang KP: Efficacy of temozolomide for recurrent embryonal brain tumors in children. Childs Nerv Syst; 2009 May;25(5):535-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The salvage therapy of recurrent embryonal brain tumors in children is disappointing.
  • Temozolomide is a newly developed chemotherapeutic agent in central nervous system tumors.
  • This study analyzed the efficacy of temozolomide on the treatment of recurrent embryonal brain tumors in children.
  • MATERIALS AND METHODS: There were eight patients, including four with medulloblastoma (MB), three with atypical teratoid/rhabdoid tumor (AT/RT) and one with supratentorial primitive neuroectodermal tumor, whose tumors recurred after surgery and radiotherapy, with or without conventional intravenous cisplatin-based chemotherapy.
  • RESULTS: The median treatment cycles received by these eight patients were 17 (range from two to 59 cycles).
  • The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment.
  • When conventional chemotherapy fails and/or the adverse response is too severe to tolerate, temozolomide is a reasonable alternative.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Rhabdoid Tumor / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Disease-Free Survival. Female. Follow-Up Studies. Headache / chemically induced. Humans. Magnetic Resonance Imaging. Male. Nausea / chemically induced. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] N Engl J Med. 1994 Mar 31;330(13):892-5 [8114859.001]
  • [Cites] Childs Nerv Syst. 2005 Apr;21(4):272-93 [15682321.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):470-5 [17882660.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Oncologist. 2003;8(2):174-86 [12697942.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Oct;24(7):591-3 [12368706.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):280-6 [12924701.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14 ):2335-42 [16899365.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Neoplasma. 2002;49(2):117-20 [12088104.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Acta Neurol Belg. 2007 Jun;107(2):51-4 [17710841.001]
  • (PMID = 19107490.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


20. Yano S, Hida K, Kobayashi H, Iwasaki Y: Successful multimodal therapies for a primary atypical teratoid/rhabdoid tumor in the cervical spine. Pediatr Neurosurg; 2008;44(5):406-13
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful multimodal therapies for a primary atypical teratoid/rhabdoid tumor in the cervical spine.
  • Atypical teratoid/rhabdoid tumor (AT/RT) occurring in the central nervous system is a high-grade malignant tumor, and its prognosis is poor for patients younger than 3 years of age.
  • In this article, we present a case of infant AT/RT in the cervical spine and its successful treatment by intensive chemotherapy.
  • The patient, a 1.75-year-old girl, developed an acute, progressive tetraparesis.
  • Continuously, she received intensive chemotherapy using thiotepa with autologous bone marrow transplantation.
  • At the age of nearly 3 years, she received radiation therapy to the local tumor bed and craniospinal axis.
  • The success of this treatment for the patient was that we could prevent tumor recurrence until she was able to receive radiotherapy.
  • [MeSH-major] Cervical Vertebrae / pathology. Rhabdoid Tumor / drug therapy. Spinal Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Infant

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18703889.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


21. Dang T, Vassilyadi M, Michaud J, Jimenez C, Ventureyra EC: Atypical teratoid/rhabdoid tumors. Childs Nerv Syst; 2003 Apr;19(4):244-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DISCUSSION: Over the past decade, atypical teratoid/rhabdoid tumors (ATRTs) of the central nervous system have emerged as a distinct entity.
  • This is of clinical importance because the prognosis of a patient with an ATRT is worse than that of a PNET/medulloblastoma despite aggressive surgical treatment with or without adjuvant chemotherapy and radiation therapy.
  • [MeSH-major] Brain Neoplasms. Rhabdoid Tumor. Teratoma
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Male. Medulloblastoma / diagnosis. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3461-7 [12429635.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14 (1):107-15 [8427070.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):265-75 [10066100.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):482-8 [10805090.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):369-78 [9206002.001]
  • (PMID = 12682757.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Carstensen H, Juhler M, Bøgeskov L, Laursen H: A report of nine newborns with congenital brain tumours. Childs Nerv Syst; 2006 Nov;22(11):1427-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most studies on congenital neoplastic disease deal with several types of neoplasms and are dominated by leukaemias, retinoblastomas and systemic solid tumours.
  • During the same period, a total of 172 children below the age of 15 years were diagnosed as having primary central nervous system tumours.
  • In one case, the mother was treated for cancer of the ovary with surgery and chemotherapy 2 months before conception.
  • DIAGNOSIS AND TREATMENT: Three babies were treated with complete tumour resection.
  • The histological diagnoses were teratoma in four cases, GBM in two cases, anaplastic astrocytoma in two cases and, finally, haemangioma capillare in one case.
  • OUTCOME: Four of the patients (44%) are still alive, including two patients with totally resected combined orbital/intracranial teratomas, one patient with a totally resected haemangioma and one patient with anaplastic astrocytoma who did not receive any treatment apart from supportive care.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2006 Nov;22(11):1433 [16804714.001]
  • [Cites] J Neurol Sci. 2001 Jul 15;188(1-2):13-9 [11489279.001]
  • [Cites] Prenat Diagn. 1997 Oct;17 (10 ):967-71 [9358578.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10):507-13 [9403197.001]
  • [Cites] J Neuropathol Exp Neurol. 1964 Apr;23:280-92 [14137675.001]
  • [Cites] J Perinat Med. 2003;31(3):261-5 [12825484.001]
  • [Cites] Pathology. 1992 Oct;24(4):247-53 [1289765.001]
  • [Cites] Prenat Diagn. 2002 Nov;22(11):979-83 [12424760.001]
  • [Cites] Clin Neuropathol. 2001 Sep-Oct;20(5):181-9 [11594502.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):149-52 [11981623.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):171-8 [10758320.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Jul-Sep;9(3):209-16 [1524999.001]
  • [Cites] Neurocirugia (Astur). 2003 Feb;14(1):33-40 [12655382.001]
  • [Cites] Pediatr Neurol. 2000 Jan;22(1):72-4 [10669211.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1396-400 [9529034.001]
  • [Cites] Med Pediatr Oncol. 2000 Apr;34(4):250-4 [10742060.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] Semin Perinatol. 1999 Aug;23(4):286-98 [10475542.001]
  • (PMID = 16804715.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Sasani M, Oktenoglu T, Ozer AF, Sarioglu AC: Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature. Pediatr Neurosurg; 2007;43(2):149-54
Genetic Alliance. consumer health - Rhabdoid tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical teratoid/rhabdoid tumor of the central nervous system is a highly malignant neoplasm and that usually arises in the posterior fossa, survival from this is frequently poor.
  • The patient underwent radical surgical intervention followed by chemotherapy.
  • It is possible the favorable outcome of the patient resulted from a rapid diagnosis, prompt management, radical surgical intervention and aggressive chemotherapy.
  • [MeSH-major] Frontal Lobe / surgery. Parietal Lobe / surgery. Rhabdoid Tumor / surgery. Supratentorial Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Actins / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Humans. Infant. Keratins / analysis. Magnetic Resonance Imaging. Microsurgery. Mitotic Index. Necrosis. Neurologic Examination. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337931.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


24. Morgenstern DA, Gibson S, Brown T, Sebire NJ, Anderson J: Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer; 2010 Jan;54(1):29-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant rhabdoid tumours (MRT) and their central nervous system (CNS) counterparts atypical teratoid/rhabdoid tumours (ATRT) are rare, highly aggressive malignant neoplasms of childhood.
  • Although there are isolated reports of long-term survival with intensive, multimodal therapy, outcomes are generally poor.
  • PROCEDURE: We conducted a retrospective review of all patients diagnosed with MRT/ATRT at Great Ormond Street Hospital over the 20 years from 1989 to 2009.
  • There were four long-term survivors (>30 months), all of whom received chemotherapy with or without surgical resection or radiotherapy.
  • CONCLUSIONS: In view of poor outcomes, there is a clear need for new treatment strategies and the identification of novel molecular targets for MRT/ATRT.
  • [MeSH-major] Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Female. Humans. Immunoenzyme Techniques. Infant. Male. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19653294.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Perek D, Brozyna A, Dembowska-Baginska B, Stypinska M, Sojka M, Bacewicz L, Polnik D, Kalicinski P: [Tumours in newborns and infants up to three months of life. One institution experience]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Newborns and infants up to three months of life are a specific group of population in paediatric oncology due to immaturity of tissues and organs and rarity of neoplastic diseases in this group of patients (pts).
  • There are no strict therapeutic procedures established for these children.
  • THE AIM of our study was to examine distribution of tumours in newborns and infants up to 3 months of age treated in our institution and to present our own experience in the treatment of these patients.
  • Distribution of tumour types in newborns and babies from 1 to 3 months of age was analyzed separately.
  • Due to similar growth pattern, response to treatment and it's side effects in newborns and small infants, treatment results were evaluated for the whole group.
  • There were also 3 cases of soft tissue sarcomas (STS), 2 central nervous system tumours (CNS), 2 retinoblastoma (RB), 2 hepatoblastoma (HB).
  • In the group of 21 babies aged 1-3 months NBL was the commonest (37%) followed by RB, CNS tumours (14% of each) HB and MT (10% of each) and Wilms tumour (WT) and immature teratoma (IT) each 5%.
  • It concerned pts with MT--28, IT--3 pts, yolk sac tumour (YST)--1 pt and malignant tumours (stage I and II): 8-NBL, 2-CNS tumours, 2 STS, 3-HB, 1-WT.
  • Eleven pts underwent combined treatment of chemotherapy and surgery: 5 with stage III and IV NBL, 6 with other tumours.
  • Chemotherapy alone was administered to 7 pts in whom local advancement of disease enabled surgery and to pts with RBL.
  • One pt, critically ill, died before any treatment.
  • 2. Newborns and small infants with advanced neoplastic disease, similarly to older children can be cured with chemotherapy.
  • 3. Individual approach is warranted in newborns and small infants and treatment should be carried out in specialized centres.
  • 4. All patients who completed treatment of any tumour type should be followed up by a pediatric oncologist.
  • [MeSH-major] Infant Welfare / statistics & numerical data. Neoplasms / epidemiology. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317902.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down






Advertisement